Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Nov;95(44):e5228.
doi: 10.1097/MD.0000000000005228.

Dexrazoxane improves cardiac autonomic function in epirubicin-treated breast cancer patients with type 2 diabetes

Fangyi Sun  1 , Jing Shi, Cuizhi Geng
Affiliations
Randomized Controlled Trial

Dexrazoxane improves cardiac autonomic function in epirubicin-treated breast cancer patients with type 2 diabetes

Fangyi Sun et al. Medicine (Baltimore). 2016 Nov.

Abstract

Objective: The study objective was to investigate the protective effects of dexrazoxane (DRZ) on the cardiac autonomic nervous system (ANS) activity in anthracycline-treated breast cancer patients with diabetes.

Methods: A total of 110 early stage breast cancer patients with type 2 diabetes were divided randomly into 2 even groups: chemotherapy alone (Chemo) and chemotherapy + DRZ (Chemo + DRZ). All patients underwent adjuvant chemotherapy (80 mg/m epirubicin and 500 mg/m cyclophosphamide) for a total of 6 cycles with 21 days/cycle. The Chemo + DRZ group patients were treated intravenously with 800 mg/m DRZ 30 minutes prior to the administration of epirubicin, while the Chemo group patients were given saline. The cardiac ANS function was evaluated for each patient before and after 6 cycles of chemotherapy by resting heart rate (RHR) and heart rate variability (HRV), which was evaluated by both time and frequency domains.

Results: Before and after chemotherapy, patients in both groups showed significant decreases in HRV indices and increases in RHR and the low-frequency/high-frequency ratio. There were no significant differences between Chemo and Chemo + DRZ groups in terms of RHR and HRV indices before chemotherapy; however, after chemotherapy, patients in the Chemo group had a higher average RHR and lower HRV indices compared with patients in the Chemo + DRZ group.

Conclusion: DRZ protects the cardiac ANS in epirubicin-treated early stage breast cancer patients with diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flowchart showing the selection of patients for each study group. DM2 = type 2 diabetes.
See this image and copyright information in PMC

References

    1. Hayek ER, Speakman E, Rehmus E. Acute doxorubicin cardiotoxicity. N Engl J Med 2005; 352:2456–2457. - PubMed
    1. Kaklamani VG, Gradishar WJ. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer? Clin Breast Cancer 2003; 4 (suppl 1):S26–S33. - PubMed
    1. Postma A, Elzenga NJ, Haaksma J, et al. Cardiac status in bone tumor survivors up to nearly 19 years after treatment with doxorubicin: a longitudinal study. Med Pediatr Oncol 2002; 39:86–92. - PubMed
    1. Brouwer CA, Gietema JA, van den Berg MP, et al. Long-term cardiac follow-up in survivors of a malignant bone tumour. Ann Oncol 2006; 17:1586–1591. - PubMed
    1. Syvanen K, Ekholm E, Anttila K, et al. Immediate effects of docetaxel alone or in combination with epirubicin on cardiac function in advanced breast cancer. Anticancer Res 2003; 23:1869–1873. - PubMed

Publication types

MeSH terms